Clinicians should adopt a risk-based, rather than biopsy-first, approach to encourage biopsy acceptance and improve early ...

A clinician nudge for referral to a gynecologic oncologist at the time of suspected ovarian cancer diagnosis improved ...

Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with ...

Results from the NRG Oncology GOG-0263 Phase III clinical trial testing the addition of cisplatin-based chemotherapy to ...

Toon Van Gorp, MD, PhD, discussed findings from the MIRASOL trial and the potential of mirvetuximab to redefine treatment ...

Moore, MD, discusses the exciting advancements in endometrial cancer treatment, particularly over the past 2 years, as she ...

trial evaluating the investigational combination of avutometinib plus defactinib in patients with recurrent low-grade serous ovarian cancer (LGSOC), at the Society of Gynecologic Oncology (SGO ...

A first-line regimen involving pembrolizumab (Keytruda) and olaparib (Lynparza) significantly reduced the risk of disease ...

A combination, triplet therapy that targets cancer cells from within and without caused tumors to shrink or stabilize in ...

today announced updated clinical data from Part 1b of the ongoing DENALI clinical trial of azenosertib in patients with PROC in an oral presentation at the Society of Gynecologic Oncology (SGO ...